Mary Kay Ladone
CIK: 0001760737
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Sep 9, 2026KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
Award(A)Direct7.2K shares- - Sep 8, 2026KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
Sale(S)Direct3.9K shares at avg. $25.20$98K - Jun 5, 2026INGN
Inogen Inc
Award(A)Direct28.1K shares- - Jun 3, 2026BVS
Bioventus Inc.
Award(A)DirectRestricted Stock Units
25.1K shares- - Jun 2, 2026BVS
Bioventus Inc.
Exercise(M)Direct32.3K shares- - Jan 2, 2026NOVT
NOVANTA INC
Exercise(M)Direct1.3K shares- - Jan 2, 2026NOVT
NOVANTA INC
Award(A)DirectRestricted Stock Units
1.8K shares- - Sep 4, 2025KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
Award(A)Direct10.9K shares- - Jul 11, 2025NOVT
NOVANTA INC
Exercise(M)Direct572 shares- - Jun 3, 2025BVS
Bioventus Inc.
Award(A)DirectRestricted Stock Units
32.3K shares- - Jun 2, 2025BVS
Bioventus Inc.
Exercise(M)Direct26.5K shares- - May 14, 2025INGN
Inogen Inc
Award(A)Direct30.6K shares- - Jan 2, 2025NOVT
NOVANTA INC
Award(A)DirectRestricted Stock Units
1.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 9, 2026 |  KMTS KESTRA MEDICAL TECHNOLOGIES, LTD. | Award(A) | 7,217 | - | $0 | Direct |
| Sep 8, 2026 | KMTS KESTRA MEDICAL TECHNOLOGIES, LTD. | Sale(S) | 3,908 | $25.20 | $98,464 | Direct |
| Jun 5, 2026 |  INGN Inogen Inc | Award(A) | 28,081 | - | $0 | Direct |
| Jun 3, 2026 |  BVS Bioventus Inc. | Award(A) Restricted Stock Units | 25,146 | - | - | Direct |
| Jun 2, 2026 | BVS Bioventus Inc. | Exercise(M) | 32,282 | - | $0 | Direct |
| Jan 2, 2026 |  NOVT NOVANTA INC | Exercise(M) | 1,325 | - | $0 | Direct |
| Jan 2, 2026 | NOVT NOVANTA INC | Award(A) Restricted Stock Units | 1,799 | - | - | Direct |
| Sep 4, 2025 | KMTS KESTRA MEDICAL TECHNOLOGIES, LTD. | Award(A) | 10,909 | - | - | Direct |
| Jul 11, 2025 | NOVT NOVANTA INC | Exercise(M) | 572 | - | - | Direct |
| Jun 3, 2025 | BVS Bioventus Inc. | Award(A) Restricted Stock Units | 32,282 | - | - | Direct |
| Jun 2, 2025 | BVS Bioventus Inc. | Exercise(M) | 26,493 | - | - | Direct |
| May 14, 2025 | INGN Inogen Inc | Award(A) | 30,612 | - | - | Direct |
| Jan 2, 2025 | NOVT NOVANTA INC | Award(A) Restricted Stock Units | 1,325 | - | - | Direct |
1-13 of 13 transactions
About Ladone Mary Kay
Ladone Mary Kay (SEC CIK 0001760737) files insider reports with the SEC as Director of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS), Director of Inogen Inc (INGN) and Director of Bioventus Inc. (BVS). Signal8 also holds filings tied to 1 other company.
Signal8 holds 10 ownership filings by Ladone Mary Kay (1 Form 3, 9 Form 4), filed between Jan 6, 2025 and Sep 10, 2026. Those filings report 13 transactions, from Jan 2, 2025 to Sep 9, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Ladone Mary Kay's filings is in KIRKLAND, WA.
Recent filings by Ladone Mary Kay
- Sep 9, 2026: Grant or award of KMTS shares (Form 4, code A).
- Sep 8, 2026: Open-market sale of KMTS shares (Form 4, code S).
- Jun 5, 2026: Grant or award of INGN shares (Form 4, code A).
- Jun 3, 2026: Grant or award of BVS derivative securities (Form 4, code A).
- Jun 2, 2026: Option exercise of BVS shares (Form 4, code M).
Other insiders filing for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)
- Mahboob Vaseem, Chief Financial Officer
- Umberger Traci S
- Webster Brian Daniel
- COHEN RAYMOND W, Director
- Kwo Elizabeth, Director
- Schwartz Jeffrey Lawrence, Director